In more than 70 countries, Médecins Sans Frontières provides medical humanitarian assistance to save lives and ease the suffering of people in crisis situations.
We set up the MSF Access Campaign in 1999 to push for access to, and the development of, life-saving and life-prolonging medicines, diagnostic tests and vaccines for people in our programmes and beyond.
Based in Paris, CRASH conducts and directs studies and analysis of MSF actions. They participate in internal training sessions and assessment missions in the field.
Based in Geneva, UREPH (or Research Unit) aims to improve the way MSF projects are implemented in the field and to participate in critical thinking on humanitarian and medical action.
Based in Brussels, MSF Analysis intends to stimulate reflection and debate on humanitarian topics organised around the themes of migration, refugees, aid access, health policy and the environment in which aid operates.
This logistical and supply centre in Brussels provides storage of and delivers medical equipment, logistics and drugs for international purchases for MSF missions.
This supply and logistics centre in Bordeaux, France, provides warehousing and delivery of medical equipment, logistics and drugs for international purchases for MSF missions.
This logistical centre in Amsterdam purchases, tests, and stores equipment including vehicles, communications material, power supplies, water-processing facilities and nutritional supplements.
BRAMU specialises in neglected tropical diseases, such as dengue and Chagas, and other infectious diseases. This medical unit is based in Rio de Janeiro, Brazil.
Our medical guidelines are based on scientific data collected from MSF’s experiences, the World Health Organization (WHO), other renowned international medical institutions, and medical and scientific journals.
Providing epidemiological expertise to underpin our operations, conducting research and training to support our goal of providing medical aid in areas where people are affected by conflict, epidemics, disasters, or excluded from health care.
Evaluation Units have been established in Vienna, Stockholm, and Paris, assessing the potential and limitations of medical humanitarian action, thereby enhancing the effectiveness of our medical humanitarian work.
MSF works with LGBTQI+ populations in many settings over the last 25-30 years. LGBTQI+ people face healthcare disparities with limited access to care and higher disease rates than the general population.
The Luxembourg Operational Research (LuxOR) unit coordinates field research projects and operational research training, and provides support for documentation activities and routine data collection.
The MSF Paediatric Days is an event for paediatric field staff, policy makers and academia to exchange ideas, align efforts, inspire and share frontline research to advance urgent paediatric issues of direct concern for the humanitarian field.
The MSF Foundation aims to create a fertile arena for logistics and medical knowledge-sharing to meet the needs of MSF and the humanitarian sector as a whole.
A collaborative, patients’ needs-driven, non-profit drug research and development organisation that is developing new treatments for neglected diseases, founded in 2003 by seven organisations from around the world.
Noma is a preventable and treatable neglected disease, but 90 per cent of people will die within the first two weeks of infection if they do not receive treatment.
Warning: Undefined variable $active_link in Drupal\msf_navigation\Plugin\Block\SOCSSectionNavBlock->build() (line 52 of modules/custom/msf_navigation/src/Plugin/Block/SOCSSectionNavBlock.php).
The 'Genocide of Rwandan Tutsis 1994' case study is describing the constraints, questioning and dilemmas met by MSF during the genocide of Rwandan Tutsis in April, May and June 1994. The killings occurred in spite of the presence of UN troops in Rwanda, and the members of the UN Security Council were slow to call the Tutsi extermination ‘genocide’, hence evading the obligation to intervene and stop the slaughter, as stipulated by international law.
MSF met with government officials and issued public statements to try to mobilise governments out of their inertia. These statements and actions resulted from numerous debates, conflicts and contradictory interpretations of the Rwandan situation and of MSF’s role in regard to major dilemma.
Questions and dilemmas:
Was it acceptable for a humanitarian organisation, to remain silent when confronted with genocide or, on the contrary, to call for armed intervention, an action that would lead to loss of human life?
Could MSF call on UN member states to pursue other means of action, thereby risking giving legitimacy to ineffective responses, given the nature of genocide?
Launched just as France proposed to intervene in Rwanda, was there a risk that MSF’s appeal for armed intervention would be appropriated for political gain?
